VRCA · Verrica Pharmaceuticals Inc.
$4.73
-0.07 (-1.36%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$75.07M
Shares
17.18M
Volume · Oct 1
28.99K
Avg daily vol (3M)
62.01K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.80
Open$4.51
Day$4.51–5.04
52W close$3.28–9.10
Avg vol 30d85K
Short int203K · 1.2% float · 4.2d
Short vol82%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$30.32M
Trailing 12 months
Net income (TTM)
−$31.18M
Trailing 12 months
Revenue growth YoY
-53.8%
Year over year
Operating margin
-93.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+124.5%
Year over year · more shares
Price change (1Y)
+11.3%
Trailing year
Short interest
1.2%
Latest settlement · 4.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−4%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
26%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−18%
trailing
YTD return
−42%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$210.9K over 90 days · 0% sells
Short interest
Falling
1.18% of float · ▼ -8.9% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+370%
Y/Y
EPS growth
+89%
Y/Y
Free cash flow
$-17.6M
Balance sheet
$30.1M
net cash
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$210.9K over 90 days · 0% sells
Short interest
Falling
1.18% of float · ▼ -8.9% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $5 · 26%
Range high $9
vs 200-day avg -21%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRCA
this stock
Verrica Pharmaceuticals Inc.
|
$75.07M | -42.3% | +370.2% | — | 1.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRCA | +3.8% | -8.5% | -17.8% | -12.2% | -42.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.5% | -8.6% | -29.9% | -11.6% | -54.1% |